Loading...

iCAD

DB:HWT1
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HWT1
DB
$114M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • iCAD has significant price volatility in the past 3 months.
HWT1 Share Price and Events
7 Day Returns
-13.6%
DB:HWT1
5%
DE Healthcare Services
0.3%
DE Market
1 Year Returns
86.6%
DB:HWT1
46.3%
DE Healthcare Services
-11.7%
DE Market
HWT1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
iCAD (HWT1) -13.6% 5.1% 37.2% 86.6% 15.3% 10.1%
DE Healthcare Services 5% 13.2% 26.7% 46.3% 83.7% 196.3%
DE Market 0.3% -2.8% -0.8% -11.7% 12.2% 6.1%
1 Year Return vs Industry and Market
  • HWT1 outperformed the Healthcare Services industry which returned 46.3% over the past year.
  • HWT1 outperformed the Market in Germany which returned -11.7% over the past year.
Price Volatility
HWT1
Industry
5yr Volatility vs Market

HWT1 Value

 Is iCAD undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for iCAD. This is due to cash flow or dividend data being unavailable. The share price is €5.338.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for iCAD's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are iCAD's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:HWT1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.56
NasdaqCM:ICAD Share Price ** NasdaqCM (2019-06-14) in USD $6
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 19.46x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of iCAD.

DB:HWT1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ICAD Share Price ÷ EPS (both in USD)

= 6 ÷ -0.56

-10.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iCAD is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • iCAD is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does iCAD's expected growth come at a high price?
Raw Data
DB:HWT1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
106.3%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 2.68x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for iCAD, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on iCAD's assets?
Raw Data
DB:HWT1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.26
NasdaqCM:ICAD Share Price * NasdaqCM (2019-06-14) in USD $6
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 1.84x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.76x
DB:HWT1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ICAD Share Price ÷ Book Value per Share (both in USD)

= 6 ÷ 0.26

22.75x

* Primary Listing of iCAD.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iCAD is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess iCAD's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. iCAD has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HWT1 Future Performance

 How is iCAD expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
106.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is iCAD expected to grow at an attractive rate?
  • iCAD's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • iCAD's earnings growth is expected to exceed the Germany market average.
  • iCAD's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:HWT1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:HWT1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 106.3%
DB:HWT1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 33.8%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 7.8%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 6.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:HWT1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:HWT1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 61 6 2
2020-12-31 44 0 3
2019-12-31 30 -6 3
DB:HWT1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 26 -5 -9
2018-12-31 26 -4 -9
2018-09-30 27 -4 -10
2018-06-30 27 -6 -15
2018-03-31 28 -6 -17
2017-12-31 28 -7 -14
2017-09-30 27 -7 -13
2017-06-30 26 -6 -9
2017-03-31 27 -5 -8
2016-12-31 26 -5 -10
2016-09-30 27 -6 -9
2016-06-30 31 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • iCAD's earnings are expected to grow significantly at over 20% yearly.
  • iCAD's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:HWT1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from iCAD Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HWT1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.31 0.31 0.31 1.00
2020-12-31 0.00 0.05 -0.05 2.00
2019-12-31 -0.36 -0.31 -0.40 2.00
DB:HWT1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.56
2018-12-31 -0.54
2018-09-30 -0.60
2018-06-30 -0.94
2018-03-31 -1.04
2017-12-31 -0.87
2017-09-30 -0.82
2017-06-30 -0.56
2017-03-31 -0.50
2016-12-31 -0.63
2016-09-30 -0.58
2016-06-30 -0.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if iCAD will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess iCAD's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
iCAD has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HWT1 Past Performance

  How has iCAD performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare iCAD's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • iCAD does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare iCAD's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare iCAD's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
iCAD's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from iCAD Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HWT1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 26.08 -9.45 17.71 8.23
2018-12-31 25.62 -9.02 17.81 9.45
2018-09-30 26.57 -9.91 15.83 9.70
2018-06-30 27.38 -15.48 16.48 9.92
2018-03-31 27.62 -17.08 17.67 10.09
2017-12-31 28.10 -14.26 18.38 9.33
2017-09-30 27.13 -13.34 19.13 9.74
2017-06-30 26.13 -9.08 18.71 9.85
2017-03-31 27.09 -8.02 18.67 9.82
2016-12-31 26.34 -10.10 17.85 9.52
2016-09-30 27.02 -9.19 18.05 9.38
2016-06-30 30.60 -6.91 18.76 9.11
2016-03-31 34.37 -33.12 19.52 9.18
2015-12-31 41.55 -32.45 21.19 9.16
2015-09-30 47.70 -30.14 21.62 8.83
2015-06-30 50.48 -29.47 22.53 8.82
2015-03-31 48.80 -2.68 21.77 8.55
2014-12-31 43.92 -1.01 20.51 8.16
2014-09-30 39.19 -5.32 19.57 7.75
2014-06-30 35.00 -6.19 17.66 7.29
2014-03-31 33.12 -7.07 16.86 7.04
2013-12-31 33.07 -7.61 16.69 7.04
2013-09-30 31.36 -5.90 16.60 6.86
2013-06-30 31.37 -6.78 17.39 7.20
2013-03-31 29.73 -7.84 17.54 7.42
2012-12-31 28.28 -9.37 16.94 7.03
2012-09-30 27.07 -8.90 18.89 8.24
2012-06-30 26.94 -33.07 18.13 8.90

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if iCAD has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if iCAD has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if iCAD improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess iCAD's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
iCAD has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HWT1 Health

 How is iCAD's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up iCAD's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • iCAD is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • iCAD's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of iCAD's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from iCAD Company Filings, last reported 2 months ago.

DB:HWT1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 4.57 16.28 11.32
2018-12-31 6.90 13.10 12.19
2018-09-30 9.77 6.09 6.81
2018-06-30 10.79 6.07 7.79
2018-03-31 11.44 6.04 8.66
2017-12-31 14.28 5.98 9.39
2017-09-30 18.00 5.97 11.26
2017-06-30 24.43 0.00 7.68
2017-03-31 25.53 0.02 9.54
2016-12-31 25.04 0.09 8.59
2016-09-30 27.73 0.25 10.48
2016-06-30 29.79 0.49 11.47
2016-03-31 30.83 0.74 12.87
2015-12-31 32.75 1.06 15.28
2015-09-30 34.60 1.40 17.54
2015-06-30 34.44 1.74 18.21
2015-03-31 61.60 2.20 20.27
2014-12-31 62.78 11.67 32.22
2014-09-30 62.43 15.43 33.44
2014-06-30 52.93 12.80 34.85
2014-03-31 49.94 15.99 38.40
2013-12-31 21.38 15.88 11.88
2013-09-30 25.35 15.71 10.21
2013-06-30 25.64 15.17 12.91
2013-03-31 27.24 15.00 12.67
2012-12-31 27.67 14.85 13.95
2012-09-30 30.10 14.60 13.79
2012-06-30 31.28 14.42 14.26
  • iCAD's level of debt (338.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (31.9% vs 338.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • iCAD has sufficient cash runway for 2.1 years based on current free cash flow.
  • iCAD has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -1.4% each year.
X
Financial health checks
We assess iCAD's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. iCAD has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HWT1 Dividends

 What is iCAD's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from iCAD dividends.
If you bought €2,000 of iCAD shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate iCAD's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate iCAD's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:HWT1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:HWT1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as iCAD has not reported any payouts.
  • Unable to verify if iCAD's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of iCAD's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as iCAD has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess iCAD's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can iCAD afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. iCAD has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HWT1 Management

 What is the CEO of iCAD's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Klein
COMPENSATION $1,633,507
AGE 64
TENURE AS CEO 0.6 years
CEO Bio

Mr. Michael S. Klein, also known as Mike, has been Executive Chairman of iCAD, Inc. since November 9, 2018. Mr. Mike is Chief Executive Officer of iCAD, Inc. since December 12, 2018. Mr. Mike was an Interim CEO of iCAD, Inc. since November 9, 2018 until December 12, 2018. He was a Director of iCAD, Inc. since September 26, 2018. Mr. Klein served as the Chief Executive Officer at SonaCare Medical, LLC since January 2012. He has served as the Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services, since December 2014. Prior to that, he was the Chief Executive Officer at US HIFU, LLC (f/k/a SonaCare Medical, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies, from December 2011 to November 2014. Mr. Klein served as the President of Radiation Oncology Division at CIVCO Medical Instruments Co., Inc. since May 2011. He served as the Chief Executive Officer and President of Xoft Inc., from December 2004 to December 2010. He served as the Chairman of the Board, Chief Executive Officer and President of R2 Technology, Inc. from May 2000 to 2004. From 1997 to 2000, he served as Vice President and General Manager of the Oncology Systems Group at Varian Medical Systems, Inc. and served as its Senior Vice President. From 1990 to 1997, he served in a series of senior management positions at Becton Dickinson and Company, including as Vice President of Sales and Marketing for BD Medical's North American Sales & Marketing Group. He held various sales, marketing, planning and business development positions with several major corporations. He serves as a Director of Sanarus Medical, Inc. He served as a Director of iCAD, Inc. since 2010 until May 15, 2014. He served as a Director of Xoft Inc., since December 2004. He served as a Director for SonaCare Medical, LLC since January 2012. He served as a Director of R2 Technology Inc. In 2008, Mr. Klein received the R&D Magazine Top 100 Award on behalf of Xoft, where honors were awarded for the 100 most technologically significant new products of 2008. He received a similar award in 2008 from Frost & Sullivan. Mr. Klein received an MBA from the New York Institute of Technology and a B.A. degree in history and education from the State University of New York, Albany. He completed his post-graduate Executive Education Studies at Harvard University and Babson College.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the iCAD management team in years:

0.5
Average Tenure
55
Average Age
  • The average tenure for the iCAD management team is less than 2 years, this suggests a new team.
Management Team

Mike Klein

TITLE
Executive Chairman & CEO
COMPENSATION
$2M
AGE
64
TENURE
0.6 yrs

Stacey Stevens

TITLE
President
COMPENSATION
$433K
AGE
50
TENURE
0.3 yrs

Richard Areglado

TITLE
Chief Financial Officer
COMPENSATION
$285K
AGE
54
TENURE
0.5 yrs

Jonathan Go

TITLE
Chief Technology Officer
COMPENSATION
$501K
AGE
55
TENURE
0.4 yrs

Annette Heroux

TITLE
Vice President of Administration
COMPENSATION
$178K
AGE
61
Board of Directors Tenure

Average tenure and age of the iCAD board of directors in years:

0.8
Average Tenure
54.5
Average Age
  • The average tenure for the iCAD board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mike Klein

TITLE
Executive Chairman & CEO
COMPENSATION
$2M
AGE
64
TENURE
0.6 yrs

Andy Sassine

TITLE
Director
COMPENSATION
$53K
AGE
54
TENURE
3.5 yrs

Rakesh Patel

TITLE
Director
COMPENSATION
$12K
AGE
44
TENURE
0.8 yrs

Susan Wood

TITLE
Director
COMPENSATION
$13K
AGE
55
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess iCAD's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. iCAD has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HWT1 News

Simply Wall St News

HWT1 Company Info

Description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer’s network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company’s digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Details
Name: iCAD, Inc.
HWT1
Exchange: DB
Founded: 1984
$101,673,501
19,016,478
Website: http://www.icadmed.com
Address: iCAD, Inc.
98 Spit Brook Road,
Suite 100,
Nashua,
New Hampshire, 03062,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ICAD Common Stock Nasdaq Capital Market US USD 13. Dec 1984
DB HWT1 Common Stock Deutsche Boerse AG DE EUR 13. Dec 1984
Number of employees
Current staff
Staff numbers
96
iCAD employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 20:38
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/05/16
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.